Kolexia
Chibaudel Benoit Oncologie médicale
Chibaudel Benoit
Oncologie médicale
Hôpital Franco-Britannique
Levallois-Perret, France
103 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Métastase tumorale Tumeurs du côlon Tumeurs du pancréas Carcinomes Tumeurs du rectum Carcinome épidermoïde Tumeurs de l'oesophage

Collaborateurs

Voir plus
Andre Thierry
Andre Thierry
Hôpital Saint-Antoine, Paris, France
Marijon Helene
Marijon Helene
Hôpital Franco-Britannique, Levallois-Perret, France
Gervais Honorine
Gervais Honorine
Hôpital Franco-Britannique, Levallois-Perret, France
Tournigand Christophe
Tournigand Christophe
Hôpital Henri Mondor, Créteil, France

Industries

Voir plus
Sanofi
36 collaboration(s)
Dernière en 2023
Roche
17 collaboration(s)
Dernière en 2023
BEIGENE
12 collaboration(s)
Dernière en 2023
BMS
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
British journal of cancer   24 février 2024
7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis
Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT) 26 - 28 February 2024   01 février 2024
608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.
ESMO open   02 juin 2023
Real-world first-line treatment of patients with BRAF -mutant metastatic colorectal cancer: the CAPSTAN CRC study.
ESMO open   08 novembre 2022
1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
390P Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
SO-22 Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer
Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022, Barcelona, Spain, 29 June -2 July 2022   01 juin 2022
P-106 Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022, Barcelona, Spain, 29 June -2 July 2022   01 juin 2022